The implication of G-quadruplex in cancers and neurodegenerative diseases

Abstract

Abstract: In the last decade, translational medicine came into the limelight, aiming to bridge the gap between basic research and clinical application. The association of G-quadruplex with life-threating and debilitating diseases is an emerging topic in translational medicine. Since the formation of G-quadruplex can inhibit telomerase activity, the ligands that can stabilize G-quadruplex have great significance for cancer therapeutics. In addition, growing evidence suggests the implication of quadruplex in neurodegenerative diseases. In this review, the research of G-quadruplex in the fields of anti-tumor drugs and neurodegenerative diseases is discussed.

Key words: G-quadruplex, small molecule ligands, anti-tumor drugs, neurodegenerative diseases

CLC Number:

R361

References

[1] 凌宝存. 转化医学的研究及发展 [J]. 实用医药杂志 2012.doi:10.3969/j.issn.1671-4008.2012.01.060
[2] Declan Butler. Crossing the valley of death [J]. Nature 2008, 7197(7197).
[3] Heddi, B., Phan, A.T.. [J]. Journal of the American Chemical Society 2011.
[4] Neidle S, Harrison RJ, Reszka AP, Read MA. [J]. Pharmacology and Therapeutics: The Journal of the International Encyclopedia of Pharmacology and Therapeutics 2000.
[5] ZAHLER A M, WILLIAMSON J R, CECH T R. Inhibition of telomerase by G-quartet DNA structures [J]. NATURE 1991, 350(6320).
[6] Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, Neidle S. [J]. Journal of Medicinal Chemistry 1998.
[7] Perry PJ, Reszka AP, Wood AA, Read MA, Gowan SM, Dosanjh HS, Trent JO, Jenkins TC, Kelland LR, Neidle S. [J]. Journal of Medicinal Chemistry 1998.
[8] Harrison RJ, Gowan SM, Kelland LR, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 1999.
[9] Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR. [J]. Molecular pharmacology 2002.
[10] R. John Harrison, Javier Cuesta, Gianni Chessari, Martin A. Read, Sanji K. Basra, Anthony P. Reszka, James Morrell, Sharon M. Gowan, Christopher M. Incles, Farial A. Tanious. [J]. Journal of Medicinal Chemistry 2003.
[11] Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2004.
[12] Schultes CM, Guyen B, Cuesta J, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2004.
[13] Michael J.B.Moore, Christoph M.Schultes, Javier Cuesta, Francisco Cuenca, Mekala Gunaratnam. [J]. Journal of Medicinal Chemistry 2006.
[14] Kazuo Shin-ya, Konstanty Wierzba, Ken-ichi Matsuo. Telomestatin, a Novel Telomerase Inhibitor from Streptomyces anulatus [J]. Journal of the American Chemical Society 2001, 6(6).
[15] KIM M Y, VANKAYALAPATI H, SHIN-YA K. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex [J]. Journal of the American Chemical Society 2002, 124(10).
[16] WANG Y, PATEL D J. Guanine residues in d(T2AG3) and d(T2G4) form parallel-stranded potassium cation stabilized G-quadruplexes with antiglycosidic torsion angles in solution [J]. Biochemistry 1992, 31(35).
[17] ANANTHA N V, AZAM M, SHEARDY R D. Porphyrin binding to quadruplexed T4G4 [J]. Biochemistry 1998, 37(09).
[18] Wheelhouse RT., Han HY., Han FXG., Hurley LH., Sun DK.. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA [J]. Journal of the American Chemical Society 1998, 13(13).
[19] Evans SE, Mendez MA, Turner KB, Keating LR, Grimes RT, Melchoir S, Szalai VA. [J]. Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry 2007.
[20] Alexandrine Maraval, Sonia Franco, Corine Vialas, Genevieve Pratviel, Maria A. Blasco, Bernard Meunier. [J]. Organic & biomolecular chemistry 2003.
[21] Dixon IM, Lopez F, Esteve JP, Tejera AM, Blasco MA, Pratviel G, Meunier B. [J]. Chembiochem: A European journal of chemical biology 2005.
[22] Dixon IM, Lopez F, Tejera AM, Esteve JP, Blasco MA, Pratviel G, Meunier B. [J]. Journal of the American Chemical Society 2007.
[23] Fedoroff OY., Han HY., Chemeris VV., Kerwin SM., Hurley LH., Salazar M.. [J]. Biochemistry 1998.
[24] GUO Q, LU M, MARKY L A. Interaction of the dye ethidium bromide with DNA containing guanine repeats [J]. Biochemistry 1992, 31(09).
[25] Koeppel F, Riou JF, Laoui A, Mailliet P, Arimondo PB, Labit D. [J]. Nucleic Acids Research 2001.
[26] Franceschin M, Rossetti L, D'Ambrosio A, Schirripa S, Bianco A, Ortaggi G, Savino M, Schultes C, Neidle S. [J]. Bioorganic and Medicinal Chemistry Letters 2006.
[27] Bhadra K, Kumar GS. [J]. Biochimica et Biophysica Acta. General Subjects 2011.
[28] Zhang WJ, Ou TM, Lu YJ, Huang YY, Wu WB, Huang ZS, Zhou JL, Wong KY, Gu LQ. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA. [J]. Bioorganic and medicinal chemistry 2007, 16(16).
[29] PEARSON C E, SINDEN R R. Trinucleotide repeat DNA structures:dynamic mutations from dynamic DNA [J]. Current Opinion in structural Biology 1998, 8(03).
[30] Yerkes S, Vesenka J, Kmiec EB. A stable G-quartet binds to a huntingtin protein fragment containing expanded polyglutamine tracks. [J]. Journal of Neuroscience Research 2010, 2(2).
[31] Jean-Fran?ois Fisette, Daniel R Montagna, Mihaela-Rita Mihailescu, Michael S Wolfe. A G-rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicing. [J]. Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry 2012, 5/6(5/6).
[32] YU S, PRITCHARD M, KREMER E. Fragile X genotype characterized by an unstable region of DNA [J]. SCIENCE 1991, 252(5010).
[33] FU Y, KUHL D P, PIZZUTI A. Variation of the CGG repeat at the fragile X site results in genetic instability:Resolution of the Sherman paradox [J]. CELL 1991, 67(06).
[34] CHOWDHURY S, BANSAL M. Modelling studies on neurodegenerative disease-causing triplet repeat sequences d(GGC/GCC)n and d(CAG/CTG)n [J]. Journal of Biosciences 2001, 26(05).
[35] FRY M, LOEB L A. The fragile X syndrome d(CGG)n nucleotide repeats form a stable tetrahelical structure [J]. Proceedings of the National Academy of Sciences(USA) 1994, 91(11).
[36] Kettani A, Kumar RA, Patel DJ. [J]. Journal of Molecular Biology 1995.
[37] Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. [J]. Nature reviews. Genetics 2005, 10(10).
[38] WELLS R D. Mutation spectra in fragile X syndrome induced by deletions of CGG*CCG repeats [J]. Journal of Biological Chemistry 2009, 284(12).
[39] LEE S W, SONG M K, BAEK K H. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxy-nucleotides on their immunostimulatory potentials [J]. Journal of Immunology 2000, 165(07).
[40] DALPKE A H, ZIMMERMANN S, ALBRECHT I. Phosphodiester CpG oligonucleotides as adjuvants:polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo [J]. IMMUNOLOGY 2002, 106(01).
[41] JULIANO R L, YOO H. Aspects of the transport and delivery of antisense oligonucleotides [J]. Current Opinion in Molecular Therapeutics 2000, 2(03).
[42] BIESSEN E A, VIETSCH H, KUIPER J. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors [J]. Molecular Pharmacology 1998, 53(02).
[43] Kaur H, Jaso-Friedmann L, Evans DL. [J]. Fish & Shellfish Immunology 2003.
[44] PAPADOPOULOS K, MITA A, RICART A. Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543):A protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors [J]. Molecular Cancer Therapautics 2007, 6(12).
[45] LABER D A, TAFT B S, KLOECKER G H. Pharmacokinetics of the anti-nucleolin aptamer AS1411 in a phase I study [J]. Molecular Cancer Therapautics 2007, 6(12).